
跨診斷團體認知行為療法在初級保健中治療情緒障礙的成本效益:一項基於PsicAP臨床試驗的分析 Cost-effectiveness of transdiagnostic group cognitive behavioral therapy for emotional disorders in primary care: An analysis of the PsicAP clinical trial ——《諮詢與臨床心理學雜誌》第94卷,第2期,2026年2月—— <Journal of Consulting and Clinical Psychology> Volume 94, Issue 2, February 2026 【摘要】目的:跨診斷認知行為療法已被證實是治療情緒障礙的有效手段。然而,團體式跨診斷認知行為療法的成本效益尚不明確。鑑於在資源有限的背景下,初級保健領域對心理護理的需求日益增長,對跨診斷團體認知行為療法(TD-GCBT)進行經濟學評價,將為治療決策提供有價值的數據支持。目的:對 PsicAP 治療方案進行經濟學評價。方法:PsicAP-Costs是一項多中心、隨機對照試驗,共納入429名疑似患有焦慮症、抑鬱症和/或軀體形式障礙的患者。參與者被隨機分配至常規治療組(TAU [對照組])或TD-GCBT加常規治療組(TD-GCBT+TAU [實驗組])。治療方案包括在12至14周的時間跨度內,進行7次TD-GCBT療程。結果:TD-GCBT+TAU組的主要療效指標顯著優於對照組,在減輕抑鬱、焦慮和軀體化症狀方面,其效應量介於小至大之間。經濟學評價結果顯示,該療法產生的平均增量效益為 0.06 個質量調整生命年(QALY),平均增量成本為263歐元。據此計算得出的增量成本效益比為每質量調整生命年4,759歐元。結論:將TD-GCBT整合至常規治療(TAU)中,構成了一種具有成本效益的治療策略。其每質量調整生命年4,759歐元的增量成本效益比,遠低於西班牙公認的支付意願閾值(該閾值範圍為20,000至25,000歐元)。在此閾值下,該干預措施具有成本效益的概率很高,介於86%至89%之間。因此,在初級保健(PC)領域實施TD-GCBT,有望成為提升情緒障礙護理質量的一項具有成本效益的方案。 【關鍵詞】情緒障礙,跨診斷認知行為療法,成本分析,隨機對照試驗 [Abstract] Objective/s: Transdiagnostic cognitive behavioral therapy has proven to be an effective treatment for emotional disorders. However, the cost-effectiveness of group Transdiagnostic cognitive behavioral therapy remains unknown. Given the growing demand for psychological care in primary care in the context of limited resources, an economic evaluation of transdiagnostic group cognitive behavioral therapy (TD-GCBT) would provide valuable data for treatment decision making. Aims: To conduct an economic evaluation of the PsicAP treatment protocol. Method: The PsicAP-Costs was a multicenter, randomized controlled trial of 429 patients with a suspected diagnosis of anxiety, depression, and/or somatoform disorders. Participants were randomized to treatment as usual (TAU [control group] or TD-GCBT plus TAU [experimental group]). Treatment consisted of seven sessions of TD-GCBT delivered over a 12-14 week period. Results: The primary efficacy outcomes were significantly better in the TD-GCBT + TAU group, with small to large effect sizes for the reduction of depression, anxiety, and somatization symptoms. The economic evaluation yielded a mean incremental effectiveness of .06 quality-adjusted life years with a mean incremental cost of 263�. This resulted in an incremental cost-effectiveness ratio of 4,759� per quality-adjusted life year. Conclusions: The integration of TD-GCBT into TAU represents a cost-effective therapeutic approach. The incremental cost-effectiveness ratio of 4,759� per quality-adjusted life years is well below the willingness-to-pay threshold accepted in Spain, which ranges from 20,000� to 25,000�. At this threshold, the probability that the intervention is cost-effective is high, ranging from 86% to 89%. Therefore, the implementation of TD-GCBT in PC may represent a cost-effective option for improving the quality of care for emotional disorders. [Key words] emotional disorders, transdiagnostic cognitive behavioral therapy, cost analysis, randomized controlled trial 論文原文:Ruiz-Rodríguez, P., Muñoz-Navarro, R., Esteller-Collado, G., et al. (2026). Cost-effectiveness of transdiagnostic group cognitive behavioral therapy for emotional disorders in primary care: An analysis of the PsicAP clinical trial. Journal of Consulting and Clinical Psychology, Volume 94, Issue 2, Pages 101–113. February 2026. https://doi.org/10.1037/ccp0000990 (翻譯兼責任編輯:MARY) (需要英文原文的朋友,請聯繫微信:millerdeng95或iacmsp)

|